Novavax, CPL complete Indian vax facility

A facility for the manufacture of vaccines using Novavax's virus-like particle technology is currently undergoing validation outside Ahmadabad, India. The plant has the capacity to produce 60 million doses per year.

CPL Biologicals, a joint venture Cadila Pharmaceuticals and Novavax, announced completion of construction. The JV plans to produce seasonal and pandemic flu vaccines.

Cadila says the VLP recombinant technology will permit fast vaccine-production response for pandemics. But CPL is still lacking Indian regulatory approval to conduct clinical trials in-country for VLP-based swine flu vaccine. Meanwhile, Indian drugmakers have recently come online as producers of egg-based flu vaccines.

- here's the article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.